Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease

Table 4

(a) Meta-analysis of CHD risk for the PPARG Pro12Ala polymorphism under the dominant model.

	Cases		Controls			Odds ratio	Odds ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
ADVANCE, Men	165	693	96	426	7.1%	1.07 [0.81, 1.43]
ADVANCE, Women	78	366	87	362	5.4%	0.86 [0.60, 1.21]
Bluher et al., Men + Women	27	201	24	164	1.8%	0.91 [0.50, 1.64]
Li et al., Men + Women	23	218	38	626	1.4%	1.83 [1.06, 3.14]
Pischon et al., Men	63	250	95	502	3.7%	1.44 [1.00, 2.07]
Pischon et al., Women	58	245	99	485	4.0%	1.21 [0.84, 1.75]
PRIME, Men	47	245	108	486	4.6%	0.83 [0.57, 1.22]
Ridker et al., Men	98	523	482	2092	12.3%	0.77 [0.60, 0.98]
Ruiz et al., Men + Women	365	1805	335	1805	20.9%	1.11 [0.94, 1.31]
Tobin et al., Men + Women	113	547	124	505	8.0%	0.80 [0.60, 1.07]
Vogel et al., Men	197	786	216	880	12.0%	1.03 [0.82, 1.28]
Vogel et al., Women	64	245	208	789	5.7%	0.99 [0.71, 1.37]
Vos et al., Men	126	563	134	646	7.6%	1.10 [0.84, 1.45]
Zafarmand et al., Women	44	211	376	1519	5.7%	0.80 [0.56, 1.14]
Total (95% CI)		6898		11287	100.0%	1.00 [0.93, 1.08]
Total events	1468		2422
Heterogeneity: Chi^2 = 22.10, df = 13 (𝑃=.05); 𝐼^2=41%
Test for overall effect: 𝑍=0.06 (𝑃=.95)

(b) Meta-analysis of CHD risk for the PPARG Pro12Ala polymorphism under the recessive model.

	Cases		Controls			Odds ratio	Odds ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
ADVANCE, Men	11	693	4	426	4.9%	1.70 [0.54, 5.38]
ADVANCE, Women	1	366	5	362	5.0%	0.20 [0.02, 1.68]
Bluher et al., Men + Women	4	201	2	164	2.2%	1.64 [0.30, 9.09]
Li et al., Men + Women	0	218	2	626	1.3%	0.57 [0.03, 11.95]
Pischon et al., Men	4	250	4	502	2.6%	2.02 [0.50, 8.16]
Pischon et al., Women	4	245	6	485	4.0%	1.33 [0.37, 4.74]
PRIME, Men	7	245	4	486	2.6%	3.54 [1.03, 12.23]
Ridker et al., Men	6	523	31	2092	12.3%	0.77 [0.32, 1.86]
Ruiz et al., Men + Women	24	1805	25	1805	24.8%	0.96 [0.55, 1.69]
Tobin et al., Men + Women	10	547	4	505	4.1%	2.33 [0.73, 7.48]
Vogel et al., Men	21	786	12	880	11.1%	1.99 [0.97, 4.06]
Vogel et al., Women	2	245	15	789	7.1%	0.42 [0.10, 1.87]
Vos et al., Men	21	563	12	646	10.8%	2.05 [1.00, 4.20]
Zafarmand et al., Women	3	211	30	1519	7.2%	0.72 [0.22, 2.37]
Total (95% CI)		6898		11287	100.0%	1.29 [0.99, 1.67]
Total events	118		156
Heterogeneity: Chi^2 = 15.93, df = 13 (𝑃=.25); 𝐼^2=18%
Test for overall effect: 𝑍=1.90(𝑃=.06)

(c) Meta-analysis of CHD risk for the PPARG Pro12Ala polymorphism under the recessive model in men.

	Cases		Controls			Odds ratio	Odds ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
ADVANCE, Men	11	693	4	426	11.0%	1.70 [0.54, 5.38]
Pischon et al., Men	4	250	4	502	5.9%	2.02 [0.50, 8.16]
PRIME, Men	7	245	4	486	5.9%	3.54 [1.03, 12.23]
Ridker et al., Men	6	523	31	2092	27.8%	0.77 [0.32, 1.86]
Vogel et al., Men	21	786	12	880	25.0%	1.99 [0.97, 4.06]
Vos et al., Men	21	563	12	646	24.4%	2.05 [1.00, 4.20]
Total (95% CI)		3060		5032	100.0%	1.73 [1.20, 2.48]
Total events	70		67
Heterogeneity: Chi^2 = 4.93, df = 5 (𝑃=.42); 𝐼^2=0%
Test for overall effect: 𝑍=2.96 (𝑃=.003)